RSS Feeds
Lupus Nephritis
- JAMES E. BALOW, M.D.;
- HOWARD A. AUSTIN III, M.D.;
- GEORGE C. TSOKOS, M.D.;
- TATIANA T. ANTONOVYCH, M.D.;
- ALFRED D. STEINBERG, M.D.; and
- JOHN H. KLIPPEL, M.D.
Abstract
Nephritis has long been considered one of the most ominous components of systemic lupus erythematosus. Accumulations of immune complexes and lymphoid cells in several locations within the kidney are the best-described elements of lupus nephritis. The extreme diversity of the renal changes indicates that many variables are likely to be involved. Inbred strains of lupus-prone mice have provided homogeneous subjects for study of pathogenesis and response to treatment. Comparable grouping of lupus nephritis in humans according to unique or dominant pathogenetic mechanisms is imprecise and limited by insufficient knowledge of the primary stimulus for the disease. Treatment is also imperfect and, at times, hazardous. Certain regimens incorporating cytotoxic drugs provide a significant therapeutic advantage over corticosteroids alone in the management of this disease.
- adrenal cortex hormones
- amenorrhea
- autoantibodies
- azathioprine
- B lymphocytes
- chronic kidney failure
- cyclophosphamide
- drug-induced cystitis
- drug-induced neoplasms
- glomerulonephritis
- herpes zoster
- immunologic adjuvants
- immunologic cytotoxicity
- immunosuppressive agents
- lupus nephritis
- methotrexate
- murine models
- oncogenes
- prednisone
- systemic lupus erythematosus
- T lymphocytes
- urinary bladder
Article and Author Information
-
▸An edited summary of a Combined Clinical Staff Conference held on 21 May 1986 at the Clinical Center, Bethesda, Maryland, and sponsored by the National Institutes of Health, U. S. Department of Health and Human Services.
-
▸Authors who wish to cite a section of the conference and specifically indicate its author can use this example for the form of reference:
AUSTIN HA III. Murine models, pp 79-81. In: BALOW JE, moderator. Lupus nephritis. Ann Intern Med. 1987;106:79-94.
-
▸Requests for reprints should be addressed to Wendy Schubert; National Institutes of Health, Building 10, Room 1C255; Bethesda, MD 20892.
